Hepatitis C in the rituximab era

Research output: Contribution to journalComment/debatepeer-review

9 Scopus citations


In a multicenter Japanese study, Ennishi et al have demonstrated both the benefits and the risks of adding rituximab to CHOP chemotherapy (R-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL) and hepatitis C virus (HCV) infection.

Original languageEnglish (US)
Pages (from-to)5081-5082
Number of pages2
Issue number24
StatePublished - Dec 9 2010

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Hepatitis C in the rituximab era'. Together they form a unique fingerprint.

Cite this